Navigation Links
Dr. James F. Pingpank to Present at Leading Regional Therapies Conference
Date:2/19/2009

NEW YORK, Feb. 19 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for the treatment of cancers of the liver, announced today that Dr. James F. Pingpank will present at The Fourth International Symposium on Regional Cancer Therapies, to be held February 21-23, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )

Dr. Pingpank, Adjunct Principal Investigator of Delcath's Phase III Trial treating ocular and cutaneous melanoma metastatic to the liver, and Principal Investigator of the trial at the University of Pittsburgh Medical Center, will deliver two oral presentations titled:

       Impact of High-dose Melphalan (MEL) Administered via Hepatic Arterial
          Infusion for Patients with Unresectable Hepatic Metastases from
                              Neuroendocrine Tumors (MNET)

                                       and

            Multi-institutional Clinical Trials in Regional Therapy for
                                 Liver Metastases

Commenting on the relevance of these topics, Richard L. Taney, President and CEO of Delcath Systems, stated, "As we move toward completion of our pivotal Phase III Trial, Dr. Pingpank's updates provide an invaluable communication to the other leaders in the field of regional cancer treatment. Dr. Pingpank and Dr. Marybeth Hughes, Principal Investigator of the Phase III Study at the National Cancer Institute, continue to show their dedication to the trial."

The Phase III Study

The Phase III clinical study is being conducted under a Cooperative Research and Developme
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
2. Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
3. Hope for 14 Million Rosacea Sufferers: Pyratine-XR(TM) Study to be Presented at South Beach Symposium
4. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
5. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
6. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
7. EntreMed Presents Initial Clinical Results for ENMD-2076
8. Oridion Announces Significant Medical Studies Presented at STA
9. Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
10. Advances in Science and Treatment of Pain Presented at 25th Annual American Academy of Pain Medicine Meeting January 28 - 31, 2009
11. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015   Hospira, ... leader in biosimilars and the world,s leading provider ... studies that support an evaluation of biosimilarity of ... Food and Drug Administration (FDA) conditionally approved name ... EPOGEN™ (epoetin alfa). These study data were presented ...
(Date:3/27/2015)... 27, 2015 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution ... radiotherapy and diagnostic imaging centers in ... a purchase agreement under which Concord Medical Services ... the Company, agreed to acquire the Fortis Surgical ...
(Date:3/26/2015)... 26, 2015 "Whether it,s our family, our ... In a single sentence, Dr. Anthony ... at Pfizer,s Centers for Therapeutic Innovation (CTI), ... progress at America,s biopharmaceutical companies. CTI,s ... academia, patient foundations and the National Institutes of Health ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... 24, 2011 Apelon, Inc., a leading ... today announced the availability of the first ... code set management and collaborative mapping application, ... enabling widespread access to national healthcare vocabulary ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... extracellular matrix , for the diabetes, cancer, dermatology ... presentation for PEGPH20 at the 2011 EORTC-NCI-ASCO Annual Meeting, ... is a PEGylated form of rHuPH20 that is being ...
Cached Medicine Technology:Apelon Announces Availability of New TermManager® Software 2Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting 2
(Date:3/27/2015)... NE (PRWEB) March 27, 2015 Ticket Down ... at the CenturyLink Center in Omaha, Nebraska on Friday, ... possibility that more concert dates will be added in Omaha ... of fan demand. , The Garth Brooks World Tour is ... the latest announcement that Garth Brooks and Trisha Yearwood will ...
(Date:3/27/2015)... Endure Yoga is launching WOD (Workout ... This new program matches yoga poses with functional fitness ... down. This program utilizes yoga to improve recovery, prevent ... , Karen Lefurgy, competitive athlete at CrossFit ... I started Crossfit® training, but quickly, due to time ...
(Date:3/27/2015)... 27, 2015 SMI (Silicon Microstructures, Inc.), ... has launched the SM1120 MEMS based ultra-miniature pressure sensor ... microsensor profile at only 220um x 75um provides ample ... challenging locations. With industry leading in vivo drift ... provides a broad operating pressure range from 0 to ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Operatic contenders ... of greatness on April 17th. The universally acclaimed baritone ... the 9th annual Opera Idol at The Merion in ... competition, which has drawn aspiring opera singers from around ... showcases some of the finest young talent in the ...
(Date:3/27/2015)... The 2015 Deep Market Research Report ... in-depth study on the current state of the ... on the Chinese situation. , The report provides ... classifications, applications and industry chain structure. The Glutathione ... and Chinese domestic situations including development trends, competitive ...
Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:Endure Yoga Introduces WOD Recovery Yoga 2Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Opera Idol Competition At The Merion In Evanston 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3
... in our environment that may cause breast cancer . ... linked to breast cancer has listed 216 compounds, many of ... extensive review of 900 scientific studies concerning humans and rodents ... and water that appear to be a reason behind breast ...
... toll the world over. Almost 100 million girls die every year, ... ,According to a searing report on the prejudices against women, "Because ... developing countries, where a male child remains more valued. ... child development agency - highlights the fact that two million girls ...
... Researchers at University of Southern Maine in Portland have revealed ... far the US government has been denying the possibility. ... Laboratories in New Mexico found that people exposed to DU ... ,DU is a dense, inadequately radioactive metal that is ...
... of North Carolina, Chapel Hill, have found out that middle-aged ... are at a higher risk of retinopathy than others. ... of the eye that can lead to severe vision problems ... the headache history and eye health of 10,902 men and ...
... same level of active therapeutic chemical and produces the ... the harmful toxins, according to UCSF researchers. ... of the active ingredient delta-9-tertrahydrocannibinol, or THC, are reported ... and Therapeutics." ,"We showed in a recent ...
... claimed significant success in the continuing fight to develop ... ,Thomas Pento and Roger HarrisonTwo professors say ... the spread of certain cancerous cells without damaging healthy, ... in fighting lung, prostate and pancreatic cancers without the ...
Cached Medicine News:Health News:List of Compounds That Causes Breast Cancer Identified 2Health News:Female Infanticide and Feticide Continue to Increase 2Health News:History of Migraines Linked to Increased Risk of Retinopathy 2Health News:Smokeless Cannabis Delivery Device Found Efficient and Less Toxic 2Health News:US Professors Develop Fusion Protein to Fight Cancer 2
... A CMV assay for screening donors on ... CMV-PA System uses CMV antigen attached to ... cytomegalovirus. Relative sensitivity and specificity of the ... 99.8% and 99.3% respectively. The use of ...
... microplate agglutination technology. Its is a fully ... testing. PK7200 also handles weak D as ... The Automated Microplate System delivers the very ... that for the past generation has tested ...
... fully automated blood bank ... American market based on ... The ORTHO ProVue™ eliminates ... increasing productivity via random ...
... are in need of MRI exams, many ... scanners. They have heard of, or experienced ... and noisy tubes of supercon scanners - ... people want is a patient-friendly MRI. Now ...
Medicine Products: